The Utility of Subcutaneous Methotrexate for Chronic Plaque Psoriasis in a Real-World Setting.
The advent of biologic agents that target cytokines central to the psoriatic disease cascade have revolutionised the treatment of moderate to severe psoriasis. Methotrexate (MTX) remains the recommended first-line conventional systemic treatment for moderate to severe psoriasis.1 This is due to its well established efficacy, safety profile and low cost1 . Across published data, MTX demonstrates a PASI 75 of approximately 40% at weeks 12-162 , with a median drug survival of 1.8 years.3 The cost of oral MTX is less than 1%, and subcutaneous (SC) MTX less than 10% of that of the cheapest biologic agent in the Republic of Ireland. Oral MTX may be limited by its toxicity and drug survival.3.